drugset / Trial / NCT04840979
Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease
Phase 2
Active not recruiting
107 enrolled
Columbia University
National Institute on Aging (NIA) · collab
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
The primary objectives are to validate that a previously identified gene variant influences the proportion of activated microglia (PAM) and the amount of TSPO binding on PET imaging, to identify novel loci that influence PAM and TSPO PET, and to understand the functional consequences of gene variants that drive microglial activation in Alzheimer's disease.
Timeline
- Start
- 2021-05-11
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 11C-ER176 | Diagnostic / imaging agent | 740 mbq | Intravenous |
| Subject | 18F-Florbetaben | Diagnostic / imaging agent | — | — |